{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T09:10:22Z","timestamp":1760778622884,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.breast.2019.06.006","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T15:17:49Z","timestamp":1561994269000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Bisphosphonate use and incident cardiovascular events among older breast cancer survivors"],"prefix":"10.1016","volume":"47","author":[{"given":"Nana","family":"Gegechkori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Egorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Mhango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Wisnivesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.breast.2019.06.006_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.279.8.585","article-title":"Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study","volume":"279","author":"Fried","year":"1998","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.breast.2019.06.006_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318142c865","article-title":"Competing causes of death for women with breast cancer and change over time from 1975 to 2003","volume":"31","author":"Du","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib3","first-page":"86","article-title":"Comorbidities and cardiovascular disease risk in older breast cancer survivors","volume":"20","author":"Haque","year":"2014","journal-title":"Am J Manag Care"},{"issue":"22","key":"10.1016\/j.breast.2019.06.006_bib4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2019.06.006_bib5","series-title":"Paper presented at: mayo clinic proceedings","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","author":"Drake","year":"2008"},{"issue":"15","key":"10.1016\/j.breast.2019.06.006_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2019.06.006_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib8","first-page":"22","article-title":"Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcified tissue international","volume":"90","author":"Vestergaard","year":"2012","journal-title":"Janus"},{"issue":"5","key":"10.1016\/j.breast.2019.06.006_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.1792","article-title":"Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis","volume":"28","author":"Wolfe","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.breast.2019.06.006_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/rtph.2002.1550","article-title":"Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study","volume":"35","author":"Steinbuch","year":"2002","journal-title":"Regul Toxicol Pharmacol"},{"issue":"8","key":"10.1016\/j.breast.2019.06.006_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":"Use of alendronate and risk of incident atrial fibrillation in women","volume":"168","author":"Heckbert","year":"2008","journal-title":"Arch Intern Med"},{"issue":"18","key":"10.1016\/j.breast.2019.06.006_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2019.06.006_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.breast.2019.06.006_bib14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.breast.2019.06.006_bib16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00198-014-3020-y","article-title":"Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study","volume":"26","author":"Herrera","year":"2015","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.breast.2019.06.006_bib17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.13-0675","article-title":"Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis","volume":"144","author":"Sharma","year":"2013","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.breast.2019.06.006_bib18","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00198-012-1894-0","article-title":"A\u00a0population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke","volume":"23","author":"Kang","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.breast.2019.06.006_bib19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of alendronate and risk of cardiovascular events in patients with hip fracture","volume":"33","author":"Sing","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"S2","key":"10.1016\/j.breast.2019.06.006_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","article-title":"The pharmacology of bisphosphonates and new insights into their mechanisms of action","volume":"14","author":"Russell","year":"1999","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.breast.2019.06.006_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.breast.2019.06.006_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2000.15.3.599","article-title":"Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol","volume":"15","author":"Adami","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S8756-3282(02)00924-9","article-title":"Changes in serum HDL and LDL cholesterol in patients with Paget\u2019s bone disease treated with pamidronate","volume":"32","author":"Montagnani","year":"2003","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.breast.2019.06.006_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","article-title":"Effect of etidronic acid on arterial calcification in dialysis patients","volume":"26","author":"Ariyoshi","year":"2006","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.breast.2019.06.006_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","article-title":"Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption","volume":"21","author":"Price","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"year":"2009","series-title":"Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure","author":"O\u2019Neill","key":"10.1016\/j.breast.2019.06.006_bib26"},{"issue":"9","key":"10.1016\/j.breast.2019.06.006_bib27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.ki.5001841","article-title":"Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate","volume":"70","author":"Price","year":"2006","journal-title":"Kidney Int"},{"issue":"21","key":"10.1016\/j.breast.2019.06.006_bib28","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis)","volume":"56","author":"Elmariah","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.breast.2019.06.006_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0272-6386(04)00937-0","article-title":"Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis","volume":"44","author":"Nitta","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4933-4-1","article-title":"The Interleukin-6 inflammation pathway from cholesterol to aging\u2013Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases","volume":"4","author":"Omoigui","year":"2007","journal-title":"Immun Ageing"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/ENDO:23:1:01","article-title":"Osteoporosis and cardiovascular disease","volume":"23","author":"McFarlane","year":"2004","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.breast.2019.06.006_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/qjmed\/hci077","article-title":"Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies","volume":"98","author":"Hamerman","year":"2005","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.10.043","article-title":"Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells","volume":"602","author":"Wu","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.breast.2019.06.006_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jbmr.521","article-title":"Circulating gammadelta T cellsand the risk of acute-phase response after zoledronic acidadministration","volume":"27","author":"Rossini","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.breast.2019.06.006_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00223-012-9647-9","article-title":"Long-term effects of amino-bisphosphonates on circulating gammadelta T cells","volume":"91","author":"Rossini","year":"2012","journal-title":"Calcif Tissue Int"},{"issue":"570\u2013571","key":"10.1016\/j.breast.2019.06.006_bib37","article-title":"Amino-bisphosphonates and cardiovascular risk: a new hypothesis involving the effects on gamma-delta T cells","volume":"34","author":"Giollo","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.breast.2019.06.006_bib38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.mlr.0000207817.32496.cb","article-title":"Validity of a prescription claims database to estimate medication adherence in older persons","volume":"44","author":"Grymonpre","year":"2006","journal-title":"Med Care"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977619305181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977619305181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:40:46Z","timestamp":1760776846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977619305181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":38,"alternative-id":["S0960977619305181"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2019.06.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonate use and incident cardiovascular events among older breast cancer survivors","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2019.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}